NCT02479308View on ClinicalTrials.gov

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

Moxifloxacin

Single administration

DRUG

ALKS 5461

Daily administration for a total of 12 dosing days

DRUG

Placebo

Placebo will be matched to Moxifloxacin or ALKS 5461

Trial Locations (1)

66212

Alkermes Investigational Site, Overland Park

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY